No Data
No Data
US Manufacturing Index Rises To 43, Highest Since 2020
Citius Pharmaceuticals Reports Positive Early Stage Results of Cancer Combo Treatment
Express News | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients With Recurrent Solid Tumors
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients With Recurrent Solid Tumors
12 Health Care Stocks Moving In Monday's After-Market Session
Dr. Reddy's Laboratories Agreed To Partially Defer A Milestone Payment From Citius Oncology, Inc., Due On September 9, 2024, Upon FDA Approval Of LYMPHIR, Without Penalty, Pending Further Discussions, As Per Their 2021 Asset Purchase Agreement
No Data
No Data